Awaiting development: Guidance and quality standards

Showing 51 to 60 of 285

Guidance and quality standards awaiting development
Title	Type
Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over TS ID 11838	Technology appraisal guidance
Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]	Technology appraisal guidance
Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy and autologous stem cell transplant are suitable ID6249	Technology appraisal guidance
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]	Technology appraisal guidance
Depemokimab for treating chronic rhinosinusitis with nasal polyps ID 6449	Technology appraisal guidance
Depemokimab for treating severe eosinophilic asthma in people 12 years and over ID6447	Technology appraisal guidance
Dersimelagon for treating erythropoietic protoporphyria and X-linked protoporphyria in people 12 years and over TS ID 10392	Technology appraisal guidance
Deucravacitinib for treating active psoriatic arthritis TS ID 11981	Technology appraisal guidance
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154	Technology appraisal guidance
Donidalorsen for preventing hereditary angioedema attacks in people 12 years and over ID6457	Technology appraisal guidance